AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by equities research analysts at Citigroup Inc. in a note issued to investors on Thursday, September 7th, MarketBeat Ratings reports.

A number of other research analysts also recently weighed in on AZN. Shore Capital reiterated a “sell” rating on shares of AstraZeneca plc in a report on Wednesday, May 10th. Barclays PLC reiterated an “overweight” rating and set a GBX 6,000 ($80.90) price target on shares of AstraZeneca plc in a report on Thursday, May 11th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of AstraZeneca plc in a report on Thursday, May 11th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($52.58) price target on AstraZeneca plc and gave the company a “sell” rating in a report on Thursday, May 11th. Finally, Jefferies Group LLC lowered their price target on AstraZeneca plc from GBX 4,900 ($66.06) to GBX 4,700 ($63.37) and set a “hold” rating on the stock in a report on Friday, May 12th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of GBX 5,041.09 ($67.97).

AstraZeneca plc (AZN) traded up 1.41% during trading on Thursday, reaching GBX 4776.50. The company had a trading volume of 1,074,772 shares. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The stock has a 50 day moving average price of GBX 4,568.92 and a 200 day moving average price of GBX 4,884.42. The firm’s market capitalization is GBX 60.47 billion.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at

In other AstraZeneca plc news, insider Nazneen Rahman purchased 39 shares of the firm’s stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average cost of GBX 4,370 ($58.92) per share, for a total transaction of £1,704.30 ($2,297.83).

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.